{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:01Z","timestamp":1750538401832,"version":"3.41.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a perceived dose-dependent reduction in brain amyloid deposits and not upon a proven clinical effect. We believe that the amyloid-PET scans, perceived as showing decreasing amyloid deposits, are an expression of increased cerebral cell death due to aducanumab treatment, so that with time one should instead expect a worsening and not an improvement in the treated patients' condition.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004250","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T13:03:34Z","timestamp":1650632614000},"page":"625-626","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Aducanumab-Related Amyloid-Related Imaging Abnormalities"],"prefix":"10.1097","volume":"47","author":[{"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","year":"2004","journal-title":"Ann Neurol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2014.05.001","article-title":"Early detection of Alzheimer's disease using PiB and FDG PET","volume":"72","year":"2014","journal-title":"Neurobiol Dis"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","year":"2006","journal-title":"Brain"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-180050","article-title":"Circular inference in dementia diagnostics","volume":"63","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","year":"2022","journal-title":"JAMA Neurol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:00:49Z","timestamp":1750536049000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004250"}},"subtitle":["Paean or Lament?"],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004250","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}